Last reviewed · How we verify
Hospitalization and Mortality in Iron Deficient, Anemic Patients With Chronic Kidney (CKD) and Heart Failure Receiving Intravenous Iron Therapy: A Five Year Follow-up From a Pilot Study
Iron deficiency, independent of anemia, appears to increase morbidity and mortality as well as impairing health-related quality of life in chronic heart failure (CHF), and these effects are compounded when patients also experience chronic kidney disease (CKD). This study was designed to determine the effects of intravenous iron treatment on morbidity and mortality following an initial 6-month period and a longer period of up to 5 years.
Details
| Lead sponsor | Hospital Aleman |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 40 |
| Start date | 2006-03 |
| Completion | 2012-02 |
Conditions
- Iron Deficiency
- Heart Failure
- Chronic Kidney Disease
Interventions
- Iron Sucrose
- Placebo
Primary outcomes
- mortality — 5 years
Countries
Argentina